• Mon news: AZ obesity pill. 50% of drug shortages last at least 2 years. Pharmas and IRA lawsuit appeals. Novo-Ascendis biobucks deal. Wegovy reduces all-cause hospital admissions. See more on our front page

partnership

  1. Lilly partners with AC Immune

    Eli Lilly to collaborate with AC Immune for the treatment of Alzheimer’s disease. Will it succeed and create a drug to cure Alzheimer's disease?
  2. Celgene gets a booster shot from recent trial results

    In the past two weeks, Celgene has reported positive results from 3 clinical trials. This includes two studies with its partner Acceleron. https://news.alphastreet.com/celgene-gets-a-booster-shot-from-recent-positive-clinical-trial-results/
  3. Celgene's partnership with Bluebird & Juno

    Celgene announces positive results from the trials with its development partners Bluebird Bio and Juno Therapeutics in ASH 2017. I think it's an advantage for all the three companies involved; especially for Bluebird Bio.
  4. Boehringer Ingelheim and Eli Lilly collaboration

    Approximately 30 million Americans have diabetes, and nearly 24 percent of Americans with diabetes are undiagnosed. This partnership will create a model that predicts complications from type 2 diabetes
  5. Incyte's partnership with Eli Lilly

    Lilly and Incyte plans to start Phase 3 clinical program for atopic dermatitis.
  6. Next step in Lilly and Incyte partnership

    Lilly and Incyte plans to start Phase 3 clinical program for atopic dermatitis.
  7. Will this partnership help Lilly in the long run?

    Eli Lilly join hands with Nektar to co-develop NKTR-358, Because of the $400 million deal, Lilly has reduced its outlook.